REVIAN®

34
REVIAN®
REVIAN® is an Android app from Revian, Inc. in the Medical category, currently rated 2.7★ across 26 ratings. Initial signal reads as mixed reviews: supporters praise core features while critics cite stability and value gaps.
Quality Score is 34: Emerging (early traction worth watching). For a Medical app, that means early traction worth watching. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
📊 Performance Tracking LIVE
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| ⚙ Medical complexity ×1.55 | +$27K |
| 🌐 Cross-platform reach (iOS + Android) | +$43K |
| ⚙ 7.6y maintenance × ~1-person team | +$45K |
Heuristic guess from app bundle size, category, store description signals, and release-date stack era. Bumetric does not disassemble binaries — for binary-level certainty you would need an SDK intelligence tool or the manifest itself. Reasoning chain on the right. Full ruleset on /methodology.
| 🏷 Category context | Medical |
| 📦 Compact Android bundle | → Native Kotlin |
Heuristic risk score from time-since-last-update + ratings velocity proxy + Editor's Choice / curated featuring signals. Calibrated against 2024-2025 app-store ranking decay reports. Not a guarantee — a quiet app with a healthy codebase looks the same as an abandoned one until something breaks. Full math on /methodology.
| 📅 78 days since last update | Healthy release cadence |
| 👥 Small user base (26 ratings) + 7.6y old | +10% (solo-project pattern) |
How we forecast this revenue
LOW CONFIDENCEBU Investment Matrix
Insufficient data · 31/100MICRO TIERtoo early to score- 💰 Revenue: Marginal — $0 - $500/mo · MICRO tier · indicative confidence, trajectory unclear.
- ⭐ Quality: 2.73★ across 26 reviews — weak — significant quality concerns.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: Insufficient signal to assess trajectory.
- ⚠️ Risk: Moderate — no material risk signals detected.
💰 Forecast Revenue / mo
MODEL| Below-average rating (2.7★)METRIC | −$1,500 | |
| Established app (7y old)METRIC | +$800 | |
| Ad-supported / freemiumMETRIC | +$600 | |
| Pre-traction phase (26 ratings)METRIC | −$300 |
📈 Reviews Growth
LIVE⭐ Rating Trend
LIVEProfile & Insights
Identification
- App name
- REVIAN®
- Developer
- Revian, Inc.
- Bundle ID
- com.photonmd.revian
- App Store URL
- Open in App Store
- Category
- Medical
- Content rating
- Not found
- Languages
- Not found
Company
- Website
- revian.com
- Tagline
- Not found
- Description
- Not found
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Not found
Revenue
- Reported revenue signal / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- Model estimate / mo
- $103/mo
- Top-grossing rank
- Not found
- All-time revenue
- Not found
- Pricing
- Not found
Founder
Funding
Press & Links
Contacts & Socials
📝 About this app
Designed to work seamlessly together, the REVIAN RED System combines advanced patented dual wavelength Low-Level Light Therapy (LLLT) with intelligent app control to help you stay consistent with your treatment plan and take control of your hair regrowth journey.… View full description on the official store →
Tech & Domain Intel — revian.com
- Tech stack
- Google Workspace · Microsoft 365 · Meta (Facebook) Ads
Track this app’s revenue
FREE📝 Description
95
Why low confidence: only 26 ratings · no founder-verified revenue (model estimate only) · revenue figure is directional only.
REVIAN® is a small / niche Android app in the medical space with weak public traction — only 26 ratings, no founder-verified MRR, and not ranked in any monitored grossing chart. The app appears to be monetised, but public signals are too sparse for a precise revenue estimate.
Bottom line: treat all revenue, audience and acquisition-value numbers on this page as directional only — not founder-verified facts.



